Regeneron

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
10,368
Employees10,368
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
10,368
Employees10,368

REGN Key Statistics

Market cap
81.25B
Market cap81.25B
Price-Earnings ratio
14.76
Price-Earnings ratio14.76
Dividend yield
Dividend yield
Average volume
815.12K
Average volume815.12K
High today
$749.00
High today$749.00
Low today
$728.13
Low today$728.13
Open price
$738.75
Open price$738.75
Volume
569.55K
Volume569.55K
52 Week high
$754.67
52 Week high$754.67
52 Week low
$538.01
52 Week low$538.01

REGN News

Simply Wall St 18h
Regeneron Pharmaceuticals' three-year earnings growth trails the 37% YoY shareholder returns

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if the company does...

Regeneron Pharmaceuticals' three-year earnings growth trails the 37% YoY shareholder returns
Benzinga 2d
What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals

Within the last quarter, Regeneron Pharmaceuticals REGN has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Beari...

What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Benzinga 3d
Hopeful Golden Cross Forms On Regeneron Pharmaceuticals's Chart

If history is any guide, there may be good fortune ahead for shares of Regeneron Pharmaceuticals REGN. A so-called "golden cross" has formed on its chart and, n...

Hopeful Golden Cross Forms On Regeneron Pharmaceuticals's Chart

Analyst ratings

50%

of 26 ratings
Buy
50%
Hold
46.2%
Sell
3.8%

REGN Earnings

$0.00
$8.60
$17.20
$25.80
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Available Nov 3, Pre-Market
ActualAvailable Nov 3, Pre-Market

More REGN News

Simply Wall St 5d
Possible bearish signals as Regeneron Pharmaceuticals, Inc. insiders disposed of US$16m worth of stock

Over the past year, many Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold a significant stake in the company which may have piqued investors' interes...

Possible bearish signals as Regeneron Pharmaceuticals, Inc. insiders disposed of US$16m worth of stock
Benzinga 7d
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis

The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for the treatment of adult patients with prurig...

Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.